Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Stock Short Interest Declines 70.1%

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) was the target of a large decrease in short interest in October. As of October 15th, there was short interest totaling 896 shares, a decrease of 70.1% from the September 30th total of 2,997 shares. Based on an average trading volume of 879 shares, the days-to-cover ratio is currently 1.0 days. Approximately 0.4% of the shares of the stock are short sold.

Amplify Weight Loss Drug & Treatment ETF Stock Up 2.3%

Shares of NYSEARCA:THNR traded up $0.59 during trading on Friday, reaching $25.95. 1,104 shares of the company’s stock traded hands, compared to its average volume of 1,799. Amplify Weight Loss Drug & Treatment ETF has a fifty-two week low of $23.15 and a fifty-two week high of $27.94. The company has a 50-day simple moving average of $25.59 and a 200-day simple moving average of $25.33. The firm has a market cap of $5.97 million, a PE ratio of 24.31 and a beta of 0.42.

About Amplify Weight Loss Drug & Treatment ETF

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.